Cardiff Oncology
CRDF
90 hedge funds and large institutions have $29.1M invested in Cardiff Oncology in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 16 closing their positions.
683% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $238K
175% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 12
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
17% more funds holding
Funds holding: 77 → 90 (+13)
10.02% more ownership
Funds ownership: 19.25% → 29.26% (+10%)
37% less capital invested
Capital invested by funds: $45.8M → $29.1M (-$16.8M)
Top Buyers
| 1 |
BlackRock
New York
|
+$7.35M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.63M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.51M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.79M |
| 5 |
Morgan Stanley
New York
|
+$1.63M |
Top Sellers
| 1 |
LCM
Laurion Capital Management
New York
|
-$4.96M |
| 2 |
Millennium Management
New York
|
-$1.67M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$865K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$512K |
| 5 |
Goldman Sachs
New York
|
-$501K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
101
Atom Investors
Austin,
Texas
| – | -$81.7K | -15,298 | Closed |
|
|
LP
102
LMR Partners
London,
United Kingdom
| – | -$70K | -13,101 | Closed |
|
|
CAS
103
CTC Alternative Strategies
Chicago,
Illinois
| – | -$66.2K | -12,400 | Closed |
|
104
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$54K | -10,105 | Closed |
|
105
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$7 | -1,368 | Closed |
|
|
NFSG
106
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$91 | -17 | Closed |
|
CRDF Hedge Fund Activity: Q2 2024 in Review
90 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2024, worth a combined $29.1M — down 37% from $45.8M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CRDF positions and 16 closed out — a net gain of 13 holders — while 33 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $7.35M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $4.96M sold.
- 90 institutional investors held Cardiff Oncology (CRDF) as of Q2 2024, up from 77 in Q1 2024.
- Funds reported $29.1M of Cardiff Oncology stock for Q2 2024, down 37% quarter-over-quarter.
- 29 funds opened new Cardiff Oncology positions in Q2 2024 and 16 closed out, a net change of +13 holders.
- The largest Cardiff Oncology buyer in Q2 2024 was BlackRock, an estimated $7.35M added.
- The largest Cardiff Oncology seller in Q2 2024 was Laurion Capital Management, an estimated $4.96M sold.
Based on aggregated 13F filings for Q2 2024.